In ovarian cancer patients, SLC25A1 mRNA levels are also associated with resistance to platinum-based chemotherapy, and blocking CTP function enhances sensitivity of cultured ovarian carcinoma cells to platinum (Georgiades et al., 1988; Jiang et al., 2017). Here, SLC25A1 is linked to ovarian cancer.